Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cytokine Market size is expected to expand from USD 88.57 billion in 2024 to USD 235.14 billion by 2037, registering a CAGR of over 7.8% during the forecast timeline, from 2025 through 2037. Currently in 2025, the industry revenue of cytokine is assessed at USD 93.41 billion.
The growth of the market is expected to be driven by an increased incidence of cancer worldwide over the forecast period. Immunotherapies using cytokine, which are capable of regulating the immune host response to cancer cells as well as inducing tumor cell death, have been an emerging field for cancer treatment. Cancer could be a driving cause of death around the world, accounting for about 10 million deaths in 2020, or about one in six passings. The foremost common cancers are breast, lung, colon rectum, and prostate cancers.
The complex arrangement of development variables and cytokine help all tissues and organs' cellular separation and recovery. As a result, cytokine are thought to be greatly imperative in stem cell treatment. It is expected that utilizing stem cells in regenerative pharmaceuticals and specific cytokine and development components will hold noteworthy guarantees for treating numerous human illnesses. For illustration, the Boston Stem Cell Center has given stem cell treatments by combining particular cytokine, development variables, and interleukins to intercede with musculoskeletal repair. This helps in programming the repair to prepare and fitting it to the sort of sue in musculoskeletal conditions and wounds.
Cytokine Sectors: Growth Drivers and Challenges
Growth Drivers
- Increasing Penetration of Cytokine - The rising number of symptomatic, therapeutic, & prophylactic applications of cytokine is anticipated to move the development of the worldwide cytokine market amid the estimated period. For occurrence, in November 2021, Synthekine Inc. and Merck entered into a around the world inquire about collaboration and permit understanding to find, create, and commercialize novel cytokine therapeutics. The companies will to begin with see into potential treatments for immune system illnesses but can afterward go into immunology, oncology, and other signs.
- Growing Acceptance of Cytokine as Biomarkers - Cytokine are molecular messengers that allow the immune system's cells to communicate with one another and generate a coordinated, strong but independent response to target antigens. In patients with cancer, interferons and interleukins are the two types of cytokine. Cytokine are becoming more and more accepted in cancer treatment worldwide. In addition, cytokine are being used as a biomarker to diagnose the disease and this is supporting cytokine market growth.
Challenges
- High in Cost - Although cytokine have the potential to be involved in a range of applications, including cancer treatment, stem cell therapy and diagnostics, high costs associated with cytokine-based treatments and assays are expected to hamper market expansion. Cytokine tests are required for diagnosis and monitoring because cytokine play a key role in the development or regression of pathological processes, which serve as indicators on many illnesses.
- Lack of Specificity is expected to hinder the market growth in the forecast period
- Regulatory Obstructions Associated are set to hamper the cytokine market expansion in the upcoming period
Cytokine Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.8% |
|
Base Year Market Size (2024) |
USD 88.57 billion |
|
Forecast Year Market Size (2037) |
USD 235.14 billion |
|
Regional Scope |
|
Cytokine Segmentation
Therapeutic Application (Cancer, Asthma and Airway Inflammation, Arthritis);
In terms of therapeutic application, the cancer segment in the cytokine market is anticipated to hold 50% of the revenue share during the forecast period. There is an important role played in the development of cancer by a mixture of cytokine produced by the tumor microenvironment. Cytokine that respond to infection, inflammation, and immunity may be able to slow down the development of cancer. The growth of the market is supported by factors such as an increased incidence of cancer, research and funding for treatment. According to Globocan 2020, there were 19,292,789 new cases of cancer in the world. By 2040, this number is expected to rise to 28,887,940.In addition, cytokine market growth is boosted by the presence of competitors, product launches, collaboration and pipeline assets as well as research.
Cytokine Type (Tumor Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF)
In terms of cytokine type, the tumor necrosis factor - TNF segment is in the cytokine market is anticipated to hold 40% of the revenue share during the forecast period.Tumor necrosis factor-alpha is one of the first cytokine to be discovered. When administered locally, it helps to trigger the pro-inflammatory response against pathogens and mainly affects leukocytes and vascular endothelial cells. In addition, TNF cytokine are beneficial in the case of cell apoptosis, cachexia, proliferation, differentiation, lipid metabolism and coagulation. processes. Infliximab, golimumab, etanercept, enbrel and tasonermin are some of the key TNF based medicinal products. The growth is due to an increase in the incidence of cardiovascular and oncology related diseases. TNF has been studied in a number of diseases, mainly for cardiac and cancer related indications. Many biopharmaceutical companies are associated in the research and development of TNF inhibitory medications.
Our in-depth analysis of the global cytokine market includes the following segments:
|
Cytokine Type |
|
|
Therapeutic Application |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCytokine Industry - Regional Synopsis
North American Market Forecast
The cytokine market in the North America region is set to hold the largest revenue share of 35% during the forecast period. The United States is home to several publicly and privately owned businesses investing in personalized medicine, cell signaling, or other research efforts. Over the years, through microgrants, the National Institutes of Health has been supporting a number of low-scale initiatives carried out by Private Enterprises. In addition, some of the most prevalent chronic inflammatory-mediated disorders in the United States are diabetes, cardiovascular disease, arthritic and joint conditions, allergies, and chronic obstructive pulmonary disease. Because inflammation is associated with a number of disorders, major biopharma companies cooperate with many institutions or buy businesses that have extensive inflammatory product portfolios in the region.
APAC Market Statistics
The cytokine market in the Asia Pacific region is anticipated to grow significantly during the forecast period 2025-2037. In view of the increasing prevalence of chronic diseases, such as cancer, or the increased burden of cancer, the Asia Pacific region is also expected to experience strong growth in the global cytokine market. For example, cytokine therapy can help the immune system kill cancer cells or keep them from growing. As per the reports the number of people suffering from cancer is expected to grow from 26.7 million in 2021 to 29.8 million by the end of 2035.
Companies Dominating the Cytokine Landscape
- Sanofi
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc
- UCB S.A
- Novartis AG
- Pfizer Inc.
- Biocon Limited
- Amgen Inc
- GlaxoSmithKline PLC
- General Electric Company
- Johnson & Johnson
In the News
- Sanofi reported that the additional Biologics License Application for Dupixentundupilumab to be used in adults with prurigo nodularis, a chronic inflammation skin disease causing extreme itch and lesions has been given priority review by the United States Food and Drug Administration. Dupixent is a fully Human Monoclonal Antibodies that inhibit the signaling of Interleukin 4 and Interleukin 13 pathways, which are not immunosuppressants.
- Sandoz, a global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration has accepted for review its supplemental Biologics License Application for a high concentration formulation of 100 mg mLHCF of its biosimilar Hyrimoz. The application includes the indications of the reference medicine Humira not protected by orphan exclusivity, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis.
Author Credits: Radhika Pawar
- Report ID: 5867
- Published Date: Mar 19, 2025
- Report Format: PDF, PPT
